Hong Kong Mid-Caps Diverge: Biotech Expands Margins as Property Services Pivot to Defense

Hong Kong's mid-cap and specialized equities are executing divergent capital strategies in the second half of 2026, with healthcare and biotechnology firms sustaining margin expansion while property-linked service providers implement strict cost controls to navigate macroeconomic headwinds, according to recent filings and market data.

Tong Ren Tang Technologies (1666.HK)

The traditional Chinese medicine maker has maintained a resilient market performance recently, driven by stringent inventory management. The company reported total revenue of RMB 6.48B for the 2025 fiscal year, with its flagship Liuwei Dihuang pill series seeing sales jump 20.7%. According to people familiar with the matter, a nearly 40% reduction in receivables highlights its tightening operational efficiency.

Blue Moon Group (2497.HK)

The household care provider is targeting an operational turnaround, projecting its consolidated loss for the first half of 2026 to narrow by no less than 55% year-over-year. Despite ongoing profitability pressures, the company executed a dividend payout of over HKD 1.04B in 2025. Analysts are watching whether the rollout of high-margin product lines will raise its full-year forecast.

Giant Biogene (2579.HK)

Giant Biogene continues to outperform its sector peers, fueled by robust demand for its recombinant collagen products. Following a 42.4% surge in net income to RMB 2.06B in 2024, management expressed strong optimism for 2026. The company is actively capturing market share in the functional skincare segment, which cements its valuation premium.

Hysan Development (0014.HK)

Hysan Development is optimizing its balance sheet through targeted asset divestments. In July 2026, the company agreed to sell three residential units at Bamboo Grove for HKD 126M, booking an estimated gain of HKD 32.7M. Its core Causeway Bay retail portfolio remains highly defensive, with occupancy rates rising to 95%.

Poly Property Services (6049.HK) & Yuexiu Services (2575.HK)

Property management firms are retreating to defensive capital positions. Poly Property Services reported 2025 revenue of RMB 17.13B and holds nearly RMB 12.89B in cash reserves, providing substantial liquidity for potential industry consolidation. Similarly, Yuexiu Services is focused on stabilizing its collection rates and maintaining service margins near the bottom of the real estate cycle.

Scholar Education (9936.HK)

Following a net loss of RMB 77.7M in 2025, the tutoring provider is utilizing open-market operations to signal corporate confidence. In July 2026, Scholar Education repurchased shares worth approximately HKD 267K. The company is currently scaling up its non-academic tutoring and international education initiatives.

Novotech Health (2528.HK)

As one of the largest biotech CROs in the Asia-Pacific region, Novotech previously secured a USD 3B valuation following a USD 760M funding round. With global biotech funding showing nascent signs of recovery in 2026, the market is reassessing its clinical trial backlog and the potential revival of its capital market strategies.

Allied Properties (HK) (0595.HK) & Evergrande Auto (80941.HK)

Firms outside the core thematic trends are restructuring their operations. Allied Properties (HK) is accelerating the digitalization of its consumer finance and lending segments to offset offline volatility. Meanwhile, the distressed EV maker Evergrande Auto continues to navigate complex restructuring procedures, with investors awaiting further disclosures on its debt resolution plans.

This article does not constitute investment advice.